SCHEMBL1687338

SCHEMBL1687338

CC(=O)OC[C@H]1OC(OC(=N)C(Cl)(Cl)Cl)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.59
THRB P10828 1/20 0.59
HSD17B10 Q99714 1/20 0.59
NR3C1 P04150 1/20 0.51
FYN P06241 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
ADRA2B P18089 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
CA2 P00918 7/20 0.51
TSHR P16473 1/20 0.48
CA12 O43570 6/20 0.47
CA1 P00915 5/20 0.47
CA9 Q16790 4/20 0.47
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
CA4 P22748 2/20 0.45
CA5A P35218 2/20 0.45
CA7 P43166 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15747016 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL1726948 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17724779 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL20033571 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17192718 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL18105805 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL15040789 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL414930 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL8515524 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL19304535 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023098650-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND 盖鑫 2023-06-08 WO claimed
EP-3487318-B1 GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS PEPSICO INC (US) 2026-04-01 EP disclosed
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-17 US disclosed
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2025-11-20 US disclosed
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2025-05-27 US disclosed
US-20250049831-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND GE, XIN (CN) 2025-02-13 US disclosed
EP-4442262-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND Ge, Xin (CN) 2024-10-09 EP disclosed
WO-2024044536-A2 TUMOR-SEEKING GLUCOSE-DENDRONS FOR THE DELIVERY OF CHEMOTHERAPEUTICS AND IMAGING AGENT TO CANCER CELLS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-02-29 WO disclosed
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-02-15 US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 US disclosed
US-20140315255-A1 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2014-10-23 US disclosed
US-8754054-B2 Antibacterial compounds, methods of making them, and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2014-06-17 US disclosed
US-20130237490-A2 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2013-09-12 US disclosed
US-20120010163-A1 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2012-01-12 US disclosed
WO-2012006321-A2 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2012-01-12 WO disclosed
EP-1955601-A1 Use of propenylphenylglycosides for intensifying sweet sensory impressions Symrise GmbH & Co. KG (DE) 2008-08-13 EP disclosed
EP-1448644-A2 MATRIX FOR SOLID-PHASE ORGANIC SYNTHESIS Carlsberg A/S (DK) 2004-08-25 EP disclosed
WO-2003031489-A2 MATRIX FOR SOLID-PHASE ORGANIC SYNTHESIS CARLSBERG A/S (DK) 2003-04-17 WO disclosed
US-5563259-A NONCATALYTIC REACTION; PURITY PFIZER INC. (US) 1996-10-08 US disclosed
US-5298616-A Sulfated O-polysaccharide-trehaloses HOFFMANN-LA ROCHE INC. (US) 1994-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315255-A1 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF NRDC, VIP, LPO CYP2D6 3934/4885THRB 2948/4885HSD17B10 1475/4885
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA CYP2D6 625/4885THRB 1526/4885HSD17B10 3004/4885
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, FUT6 CYP2D6 1398/4885THRB 2091/4885HSD17B10 2371/4885
US-20120010163-A1 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF NRDC, VIP, LPO CYP2D6 3934/4885THRB 2948/4885HSD17B10 1475/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA CYP2D6 1758/4885THRB 1546/4885HSD17B10 2376/4885
US-20130237490-A2 NOVEL ANTIBACTERIAL COMPOUNDS, METHODS OF MAKING THEM, AND USES THEREOF NRDC, VIP, LPO CYP2D6 3934/4885THRB 2948/4885HSD17B10 1475/4885
US-20250049831-A1 ANTIVIRAL USE OF BISEPOXYLIGNAN COMPOUND, AND BISEPOXYLIGNAN COMPOSITION AND PREPARATION OF BISEPOXYLIGNAN COMPOUND ACE2, LBR, YWHAZ CYP2D6 1077/4885THRB 1900/4885HSD17B10 2699/4885
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof SOST, FUT6, SLC5A1 CYP2D6 1419/4885THRB 819/4885HSD17B10 4261/4885
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, FUT6 CYP2D6 1398/4885THRB 2091/4885HSD17B10 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.